This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
5. References
Abarzua P, LoSardo JE, Gubler ML, & Neri A. (1995). Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res, 55 :3490–94.
Abarzua P, LoSardo JE, Gubler ML, et al., (1996). Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene, 13 :2477–82.
Achison M & Hupp TR. (2003). Hypoxia attenuates the p53 response to cellular damage. Oncogene, 22:3431–40.
Adams PD, Li X, Sellers WR, et al., (1999). Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol Cell Biol, 19:1068–80.
Arris CE, Boyle FT, Calvert AH, et al., (2000). Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem, 43:2797–804.
Ball KL, Lain S, Fahraeus R, et al., (1997). Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol, 7:71–80.
Barlev NA, Liu L, Chehab NH, et al., (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell, 8:1243–54.
Bartek J, & Lukas J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3:421–29.
Bell S, Klein C, Muller L, et al., (2002). p53 contains large unstructured regions in its native state. J Mol Biol, 322:917–27.
Blagosklonny MV, Toretsky J, Bohen S, & Neckers L. (1996). Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA, 93:8379–83.
Blandino G, Levine AJ, & Oren M. (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 18:477–85.
Blaydes JP, Craig AL, Wallace M, et al., (2000). Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene, 19:3829–339.
Blaydes JP, Luciani MG, Pospisilova S, et al., (2001). Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J Biol Chem, 276:4699–708.
Brown CR, Hong-Brown LQ, & Welch WJ. (1997). Correcting temperature-sensitive protein folding defects. J Clin Invest, 99:1432–44.
Bullock AN, Henckel J, DeDecker BS, et al., (1997). Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA, 94:14338–42.
Bunz F, Hwang PM, Torrance C, et al., (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 104:263–9.
Bykov VJ, Issaeva N, Shilov A, et al., (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med, 8:282–8.
Bykov VJ, Selivanova G, & Wiman KG. (2003). Small molecules that reactivate mutant p53. Eur J Cancer, 39:1828–34.
Chan HM, & La Thangue NB. (2001). p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci, 114:2363–73.
Chene P. (2003). Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer, 3:102–9.
Cosulich SC, Worrall V, Hedge PJ, et al., (1997). Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol, 7:913–20.
Craig A, Scott M, Burch L, et al., (2003). Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO J, 4:787–92.
Donehower LA, Harvey M, Slagle BL, et al., (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356:215–221.
Dornan D, & Hupp TR. (2001). Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO, 2:139–44.
Dornan D, Shimizu H, Burch L, et al., (2003a). The proline-repeat domain of p53 binds directly to the transcription coactivator p300 and allosterically mediates DNA-dependent acetylation. Mol Cell Biol, 23:8846–61.
Dornan D, Shimizu H, Perkins ND, & Hupp TR. (2003b). DNA-dependent Acetylation of p53 by the Transcription Coactivator p300. J Biol Chem, 278:13431–41.
Dotto GP. (2000). p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta, 1471:M43–56.
Dyson HJ, & Wright PE. (2002). Insights into the structure and dynamics of unfolded proteins from nuclear magnetic resonance. Adv Protein Chem, 62:311–40.
Ferguson M, Luciani MG, Finlan L, et al., (2004). The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. Cell Cycle, 3:80–9.
Foster BA, Coffey HA, Morin MJ, & Rastinejad F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science, 286:2507–10.
Friedler A, Hansson LO, Veprintsev DB, et al., (2002). A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA, 99:937–92.
Galigniana MD, Harrell JM, O’Hagen HM, et al., (2004). Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem, 279:22483–9.
Gannon JV, Greaves R, Iggo R, & Lane DP. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J, 9:1595–602.
Gaudet F, Hodgson JG, Eden A, et al., (2003). Induction of tumors in mice by genomic hypomethylation. Science, 300:489–92.
Giannakakou P, Nakano M, Nicolaou KC, et al., (2002). Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA, 99:10855–60.
Giannakakou P, Sackett DL, Ward Y, et al., (2000). p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol, 2:709–17.
Gibson AE, Arris CE, Bentley J, et al., (2002). Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem, 45:3381–93.
Grossman SR. (2001). p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem, 268:2773–8.
Haupt Y, Maya R, Kazaz A, & Oren M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387:296–9.
Hietanen S, Lain S, Krausz E, et al., (2000). Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA, 97:8501–06.
Honorio S, Agathanggelou A, Wernert N, et al., (2003). Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene, 22:461–6.
Hartl FU & Hayer-Hartl M. (2002). Molecular chaperones in the cytosol: from nascent chain to folded protein. Science, 295:1852–8.
Hupp TR, Sparks A, & Lane DP. (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell, 83:237–45.
Janknecht R. (2002). The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol, 17:657–68.
Jones JM, Cui XS, Medina D, & Donehower LA. (1999). Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ, 10:213–22.
Jones PA. (2003). An epigenetic approach for finding tumor suppressors. Cell Cycle, 2: 25–6.
Kannan K, Amariglio N, Rechavi G, et al., (2001a). DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene, 20:2225–34.
Kannan K, Kaminski N, Rechavi G, et al., (2001b). DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene, 20:3449–55.
Kim AL, Raffo AJ, Brandt-Rauf PW, et al., (1999). Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem, 274, 34924–31.
Kontopidis G, Andrews MJ, McInnes C, et al., (2003). Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (Camb), 11:1537–46.
Koumenis C, Alarcon R, Hammond E, et al., (2001). Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol, 21:1297–310.
Kubbutat MH, Jones SN, & Vousden KH. (1997). Regulation of p53 stability by Mdm2. Nature, 387:299–303.
Kung AL, Wang S, Klco JM, et al., (2000). Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med, 6:1335–40.
Luciani MG, Hutchins JR, Zheleva D, & Hupp TR. (2000). The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol, 300:503–18.
Malumbres M, Hunt SL, Sotillo R, et al., (2003). Driving the cell cycle to cancer. Adv Exp Med Biol, 532:1–11.
McClue SJ, Blake D, Clarke R, et al., (2002). In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer, 102:463–8.
Meijer L, Borgne A, Mulner O, et al., (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem, 243:527–36.
Migliorini D, Denchi EL, Danovi D, et al., (2002). Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol, 22:5527–38.
Milner J & Medcalf EA. (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65:765–74.
Momand J, Jung D, Wilczynski S, & Niland J. (1998). The MDM2 gene amplification database. Nucleic Acids Res, 26:3453–59.
Momand J, Zambetti GP, Olson DC, et al., (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69:1237–45.
Murphy M, Ahn J, Walker KK, et al., (1999). Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev, 13:2490–501.
Neckers L. (2002). Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 8:S55–61.
Neckers L. (2003). Development of small molecule hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem, 10:733–9.
Noble ME, Endicott JA, & Johnson LN. (2004). Protein kinase inhibitors: insights into drug design from structure. Science, 303:1800–05.
Olivier M, Eeles R, Hollstein M, et al., (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat, 19:607–14.
Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, & Oren M. (1986). Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature, 320:182–4.
Pohler E, Craig A, Cotton J, et al., (2004). The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics. (in press).
Raveh T, Droguett G, Horwitz MS, et al., (2001). DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol, 3:1–7.
Rippin TM, Bykov VJ, Freund SM, et al., (2002). Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene, 21:2119–29.
Roth JF, Shikama N, Henzen C, et al., (2003). Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5. EMBO J, 22:5186–96.
Sakhi S, Bruce A, Sun N, et al., (1994). p53 induction is associated with neuronal damage in the central nervous system. Proc Natl Acad Sci USA, 91:7525–29.
Sangster TA, Lindquist S, & Queitsch C. (2004). Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays, 26:348–62.
Scott MT, Ingram A, & Ball KL. (2002). PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein. EMBO J, 21:6771–80.
Selivanova G, Iotsova V, Okan I, et al., (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med, 3:632–8.
Shieh SY, Ahn J, Tamai K, et al., (2000). The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev, 14:289–300.
Shikama N, Lutz W, Kretzschmar R, et al., (2003). Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation. EMBO J, 22:5175–85.
Shimizu H, Burch LR, Smith AJ, et al., (2002). The conformationally flexible S9–S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem, 277:28446–58.
Slee EA, & Lu X. (2003). The ASPP family: deciding between life and death after DNA damage. Toxicol Lett, 139:81–7.
Strichman-Almashanu LZ, Lee RS, Onyango PO, et al., (2002). A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res, 12:543–54.
Suzuki H, Gabrielson E, Chen W, et al., (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet, 31:141–9.
Takai H, Naka K, Okada Y, et al., (2002). Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J, 21:5195–205.
Vassilev LT, Vu BT, Graves B, et al., (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303:844–48.
Vogelstein B, Lane D, & Levine AJ. (2000). Surfing the p53 network. Nature, 408:307–10.
Wagner GP, Chiu CH, & Hansen TF. (1999). Is Hsp90 a regulator of evolvability? J Exp Zool, 285:116–18.
Waki T, Tamura G, Sato M, & Motoyama T. (2003). Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene, 22:4128–33.
Wang W, Takimoto R, Rastinejad F, & El-Deiry WS. (2003). Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol, 23:2171–81.
Whitesell L, Sutphin P, An WG, et al., (1997). Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene, 14:2809–16.
Whitesell L, Sutphin PD, Pulcini EJ, et al., (1998). The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol, 18:1517–24.
Woods DB & Vousden KH. (2001). Regulation of p53 function. Exp Cell Res, 264:56–66.
Wright PE & Dyson HJ. (1999). Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol, 293:321–31.
Yin Y, Stephen CW, Luciani MG, & Fahraeus R. (2002). p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol, 4:462–7.
Yu X, Guo ZS, Marcu MG, et al., (2002). Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst, 94/504–13.
Zhao R, Gish K, Murphy M, et al., (2000). The transcriptional program following p53 activation. Cold Spring Harb Symp Quant Biol, 65:475–82.
Zheleva DI, McInnes C, Gavine AL, et al., (2002). Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res, 60:257–70.
Zilfou JT, Hoffman WH, Sank M, et al., (2001). The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol, 21:3974–85.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer
About this chapter
Cite this chapter
Finlan, L.E., Hupp, T.R. (2005). The Life Cycle of P53: A Key Target in Drug Development. In: Los, M., Gibson, S.B. (eds) Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer, Boston, MA. https://doi.org/10.1007/0-387-23695-3_7
Download citation
DOI: https://doi.org/10.1007/0-387-23695-3_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-23384-0
Online ISBN: 978-0-387-23695-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)